M&A Deal Summary

Teva Pharmaceutical Industries Acquires Ivax

On July 26, 2005, Teva Pharmaceutical Industries acquired life science company Ivax for 7.4B USD

Acquisition Highlights
  • This is Teva Pharmaceutical Industries’ 5th transaction in the Life Science sector.
  • This is Teva Pharmaceutical Industries’ 3rd largest (disclosed) transaction.
  • This is Teva Pharmaceutical Industries’ 3rd transaction in the United States.
  • This is Teva Pharmaceutical Industries’ 1st transaction in Florida.

M&A Deal Summary
Date 2005-07-26
Target Ivax
Sector Life Science
Buyer(s) Teva Pharmaceutical Industries
Deal Type Add-on Acquisition
Deal Value 7.4B USD
Advisor(s) UBS Investment Bank (Financial)

Target

Ivax

Miami, Florida, United States
Ivax Corp. is a develops, manufactures, and markets branded and brand equivalent (generic) pharmaceuticals and veterinary products.

Search 199,165 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Teva Pharmaceutical Industries

Tel Aviv, Israel
Category Company
Founded 1901
Sector Life Science
Employees35,001
Revenue 15.8B USD (2023)
DESCRIPTION

Teva Pharmaceutical Industries is a provider of pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Teva Pharmaceutical Industries was founded in 1901 and is based in Tel Aviv, Israel.

DEAL STATS #
Overall 5 of 23
Sector (Life Science) 5 of 20
Type (Add-on Acquisition) 4 of 19
State (Florida) 1 of 1
Country (United States) 3 of 15
Year (2005) 1 of 1
Size (of disclosed) 3 of 14
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2004-01-22 Sicor

Irvine, California, United States

Sicor, Inc. is a vertically integrated specialty pharmaceutical company with expertise in the development, manufacturing and marketing of generic injectable pharmaceutical products.

Buy $3.4B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2008-01-22 CoGenesys

Rockville, Maryland, United States

CoGenesys, Inc. is a biopharmaceutical company with a broad based biotechnology platform and focused on the development of peptide- and protein-based medicines across broad therapeutic categories.

Buy -
Mergr

Product

Company

Legal